Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial

All regimens demonstrated comparable efficacy and B-cell depletion. ULRTX, despite a marginally longer time to disease, had the lowest adverse events and cost, supporting its utility in pemphigus management.